(Q38927421)

7 September 2017

title

SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment (English)

1 reference

7 September 2017

1 reference

13

1 reference

7 September 2017

Francesca Pentimalli

8

0 references

Iris Maria Forte

object named as

Iris Maria Forte

7

0 references

Maurizio Botta

12

object named as

Maurizio Botta

1 reference

7 September 2017

4

Elena Dreassi

1 reference

7 September 2017

2

Paola Indovina

1 reference

7 September 2017

5

Nadia Casini

1 reference

7 September 2017

1

Elisa Ceccherini

1 reference

7 September 2017

11

Silvia Schenone

1 reference

7 September 2017

Claudio Zamperini

3

1 reference

7 September 2017

Ornella Cutaia

6

1 reference

7 September 2017

Luca Esposito

9

1 reference

7 September 2017

Maria Sole Polito

10

1 reference

7 September 2017

publication date

1 May 2015

1 reference

Journal of Cellular Biochemistry

7 September 2017

published in

1 reference

7 September 2017

volume

116

1 reference

7 September 2017

issue

5

1 reference

7 September 2017

page(s)

856-863

1 reference

Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.

7 September 2017

cites work

1 reference

Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition

21 January 2018

1 reference

Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression

21 January 2018

1 reference

High throughput artificial membrane permeability assay for blood-brain barrier

21 January 2018

1 reference

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

21 January 2018

1 reference

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

21 January 2018

1 reference

New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization

21 January 2018

1 reference

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients

21 January 2018

1 reference

Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity

21 January 2018

1 reference

Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice

21 January 2018

1 reference

Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma

21 January 2018

1 reference

Glioblastoma and other malignant gliomas: a clinical review.

21 January 2018

1 reference

Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.

21 January 2018

1 reference

Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.

21 January 2018

1 reference

Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.

21 January 2018

1 reference

Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division

21 January 2018

1 reference

New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation.

21 January 2018

1 reference

Novel dual Src/Abl inhibitors for hematologic and solid malignancies

21 January 2018

1 reference

Which drug or drug delivery system can change clinical practice for brain tumor therapy?

21 January 2018

1 reference

Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells

21 January 2018

1 reference

Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.

21 January 2018

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors

21 January 2018

1 reference

Malignant gliomas in adults

21 January 2018

1 reference

Pathway inhibition: emerging molecular targets for treating glioblastoma

21 January 2018

1 reference

Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration

21 January 2018

1 reference

SRC directly phosphorylates Bif-1 and prevents its interaction with Bax and the initiation of anoikis

21 January 2018

1 reference

21 January 2018

A renaissance for SRC

1 reference

CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction.

21 January 2018

1 reference

Anti-apoptosis mechanisms in malignant gliomas.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCB.25042

1 reference

7 September 2017

1 reference